Notice: This company has been marked as potentially delisted and may not be actively trading. Auris Medical (EARS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends EARS vs. MTVA, CTXR, NRBO, CVKD, MIRA, UBX, CARM, PIRS, MEIP, and SYBXShould you be buying Auris Medical stock or one of its competitors? The main competitors of Auris Medical include MetaVia (MTVA), Citius Pharmaceuticals (CTXR), NeuroBo Pharmaceuticals (NRBO), Cadrenal Therapeutics (CVKD), MIRA Pharmaceuticals (MIRA), Unity Biotechnology (UBX), Carisma Therapeutics (CARM), Pieris Pharmaceuticals (PIRS), MEI Pharma (MEIP), and Synlogic (SYBX). These companies are all part of the "medical" sector. Auris Medical vs. MetaVia Citius Pharmaceuticals NeuroBo Pharmaceuticals Cadrenal Therapeutics MIRA Pharmaceuticals Unity Biotechnology Carisma Therapeutics Pieris Pharmaceuticals MEI Pharma Synlogic MetaVia (NASDAQ:MTVA) and Auris Medical (NASDAQ:EARS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Is MTVA or EARS more profitable? Auris Medical's return on equity of 0.00% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -189.12% -122.31% Auris Medical N/A N/A N/A Which has more volatility & risk, MTVA or EARS? MetaVia has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500. Comparatively, Auris Medical has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Does the MarketBeat Community prefer MTVA or EARS? Auris Medical received 417 more outperform votes than MetaVia when rated by MarketBeat users. CompanyUnderperformOutperformMetaViaN/AN/AAuris MedicalOutperform Votes41755.38% Underperform Votes33644.62% Do insiders and institutionals have more ownership in MTVA or EARS? 1.4% of MetaVia shares are held by institutional investors. Comparatively, 6.0% of Auris Medical shares are held by institutional investors. 1.1% of MetaVia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, MTVA or EARS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$12.47MN/AN/AAuris MedicalN/AN/A-$8.75MN/AN/A Does the media refer more to MTVA or EARS? In the previous week, MetaVia had 3 more articles in the media than Auris Medical. MarketBeat recorded 3 mentions for MetaVia and 0 mentions for Auris Medical. MetaVia's average media sentiment score of 0.20 beat Auris Medical's score of 0.05 indicating that MetaVia is being referred to more favorably in the media. Company Overall Sentiment MetaVia Neutral Auris Medical Neutral SummaryAuris Medical beats MetaVia on 6 of the 9 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Auris Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EARS vs. The Competition Export to ExcelMetricAuris MedicalPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.43M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.1317.19Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.195.094.784.78Net Income-$8.75M$151.83M$120.31M$225.60M Auris Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EARSAuris MedicalN/A$0.30-25.9%N/A-88.9%$3.43MN/A0.00132,200Analyst ForecastGap UpMTVAMetaViaN/A$2.21+0.9%N/AN/A$19.04MN/A0.00N/ANews CoverageGap DownCTXRCitius Pharmaceuticals1.6536 of 5 stars$2.62-6.1%$100.00+3,716.8%-86.2%$18.94MN/A-0.4720NRBONeuroBo Pharmaceuticals1.5303 of 5 stars$2.19-5.2%$10.00+356.6%-53.6%$18.87MN/A0.008Gap DownCVKDCadrenal Therapeutics1.7091 of 5 stars$11.02-1.6%$18.00+63.3%N/A$18.28MN/A-1.684News CoverageGap UpMIRAMIRA Pharmaceuticals2.6061 of 5 stars$1.10-1.8%$14.00+1,172.7%+0.5%$18.22MN/A-2.002Analyst RevisionNews CoverageUBXUnity Biotechnology3.0929 of 5 stars$1.08-3.6%$8.00+640.7%-42.5%$18.20M$240,000.00-0.8460Gap DownCARMCarisma Therapeutics3.5769 of 5 stars$0.43+6.3%$4.94+1,048.6%-85.6%$17.96M$20.27M-0.2620High Trading VolumePIRSPieris Pharmaceuticals1.2974 of 5 stars$13.60-15.7%N/A+9.7%$17.95M$42.81M-1.12140Gap DownMEIPMEI Pharma3.9163 of 5 stars$2.63-2.6%$7.00+166.2%-59.3%$17.52M$65.30M-0.39100Analyst ForecastSYBXSynlogicN/A$1.49-0.7%N/A-53.1%$17.43M$3.37M-0.366 Related Companies and Tools Related Companies MTVA Alternatives CTXR Alternatives NRBO Alternatives CVKD Alternatives MIRA Alternatives UBX Alternatives CARM Alternatives PIRS Alternatives MEIP Alternatives SYBX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EARS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Auris Medical Holding Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Auris Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
